CRISPR Therapeutics AG (CRSP) Other Operating Expenses (2016 - 2026)

CRISPR Therapeutics AG has disclosed Other Operating Expenses across 9 years of filings, most recently posting $45.9 million for Q1 2026.

• Other Operating Expenses for Q1 2026 came in at $45.9 million, down 20.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $368.7 million (up 181.0% YoY), and the FY2025 annual result was $309.7 million, up 156.68% from the prior year.
• Other Operating Expenses came in at $45.9 million for Q1 2026 at CRISPR Therapeutics AG, down from $124.2 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $141.4 million in Q2 2025 to a low of $6.8 million in Q4 2022.
• The 5-year median for Other Operating Expenses is $42.2 million (2023), against an average of $46.3 million.
• Across the five-year window, Other Operating Expenses plunged 78.56% in 2022 and soared 1092.56% in 2025, its largest moves.
• CRISPR Therapeutics AG's Other Operating Expenses stood at $6.8 million in 2022, then soared by 193.13% to $20.0 million in 2023, then slumped by 47.92% to $10.4 million in 2024, then jumped by 1092.56% to $124.2 million in 2025, then sank by 63.01% to $45.9 million in 2026.
• The last three Other Operating Expenses figures came in at $45.9 million (Q1 2026), $124.2 million (Q4 2025), and $57.1 million (Q3 2025), per Business Quant data.